E-viri
PDF
Recenzirano
Odprti dostop
-
Bonaca, Marc P; Bauersachs, Rupert M; Anand, Sonia S; Debus, E. Sebastian; Nehler, Mark R; Patel, Manesh R; Fanelli, Fabrizio; Capell, Warren H; Diao, Lihong; Jaeger, Nicole; Hess, Connie N; Pap, Akos F; Kittelson, John M; Gudz, Ivan; Mátyás, Lajos; Krievins, Dainis K; Diaz, Rafael; Brodmann, Marianne; Muehlhofer, Eva; Haskell, Lloyd P; Berkowitz, Scott D; Hiatt, William R
New England journal of medicine/The New England journal of medicine, 05/2020, Letnik: 382, Številka: 21Journal Article
Patients with peripheral artery disease who underwent revascularization were randomly assigned to receive rivaroxaban (2.5 mg twice daily) or placebo. All patients received aspirin. The primary outcome of acute limb ischemia, major amputation for vascular causes, MI, ischemic stroke, or cardiovascular death occurred less frequently with rivaroxaban.
